Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.68

-2.4%

Dec 12 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (4470)	8/14/2001 12:21:03 PM
From: Biomaven	Read Replies (1) of 52153

Bernard, The FT comment seems about right. Baycol seems to have an incidence of this side effect about 10-fold higher than the other drugs, and so I doubt if it will have much effect on the other companies other than for them to gobble up Baycol's market share. One sleeper in this area is the use of statins for dementia/Alzheimers. The beneficiary here if this pans out is ADRX (which is a great stock anyhow). Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next